TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12406833
Drug: Mepolizumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (750 mg, three intravenous doses over 20 weeks)
Study: 11762559
Drug: Intravenous itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous itraconazole 200 mg twice daily for 2 days, then once daily for 5 days
Study: 11762559
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole solution 200 mg twice daily
Study: 11762559
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole solution 200 mg once daily
Study: 11762559
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with itraconazole
Study: 17017665
Drug: Intravenous itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous itraconazole
Study: 9205678
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral prednisolone and cyclophosphamide followed by azathioprine (CCAZP)
Study: 7679560
Drug: Morphine (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.16 mg.kg‐1)
Study: 7679560
Drug: Diamorphine (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine (0.08 mg.kg‐1)
Study: 2887152
Drug: Vigabatrin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (2 to 3 g/d, stratified according to weight)
Study: 31434737
Drug: DNA/rAd5 HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA/rAd5 HIV vaccine regimen
Study: 31434737
Drug: Anti-gp140 antibody-dependent
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-gp140 antibody-dependent cellular phagocytosis
Study: 27132450
Drug: Midazolam 1
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1 μg x kg(‐1) x min(‐1) for sedation and 1 mg/mL remifentanil for analgesia with 0.05 mg/kg intravenous bolus, then continuous infusion of 0.02‐0.10 mg x kg(‐1) x h(‐1)
Study: 27132450
Drug: Midazolam 1
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1 μg x kg(‐1) x min(‐1) for sedation and 1 mg/mL remifentanil for analgesia
Study: 20032543
Drug: 12-16 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-16 weeks of pegylated interferon and ribavirin treatment
Study: 20032543
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of pegylated interferon and ribavirin treatment
Study: 12720508
Drug: Cold vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold vaccine (no deliberate warming)
Study: 12720508
Drug: Warmed vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed vaccine (37 degrees C incubator)
Study: 12720508
Drug: Rubbed vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubbed vaccine (rubbed between palms for 1 minute)
Study: 10934803
Drug: CEOV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEOV therapy (cyclophosphamide, epirubicin, vincristine, etoposide)
Study: 10934803
Drug: CEOV-CAM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEOV-CAM therapy (cyclophosphamide, ACNU, methotrexate)
Study: 10934803
Drug: CEOV-CAM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEOV-CAM therapy (limited disease)
Study: 10934803
Drug: CEOV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEOV therapy (limited disease)
Study: 8393760
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections two weeks apart
Study: 30900326
Drug: High-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caffeine citrate (80 mg/kg)
Study: 30900326
Drug: Standard-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose caffeine citrate (20 mg/kg)
Study: 22341379
Drug: Neural tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural tissue management (education, manual therapy, and nerve gliding exercises in 4 treatments over 2 weeks)
Study: 20347506
Drug: gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1000 mg/m(2) days 1 and 8 plus carboplatin AUC 5.5 day 1 (GCb)
Study: 20347506
Drug: gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1000 mg/m(2) days 1 and 8 plus paclitaxel 200 mg/m(2) day 1 (GP)
Study: 20347506
Drug: paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 225 mg/m(2) plus carboplatin AUC 6.0 day 1 (PCb)
Study: 20347506
Drug: Histology-by-treatment interaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histology-by-treatment interaction effect between GCb and PCb
Study: 10204826
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment control plus diet (C+D)
Study: 7539233
Drug: High-dose danaparoid
Normalized name: DANAPAROID
DrugBank: Danaparoid (DB06754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose danaparoid (intravenous loading dose of 2000 U followed by 2000 U administered subcutaneously twice daily)
Study: 7539233
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (intravenous loading dose of 2500 U followed by dose-adjusted continuous infusion)
Study: 7539233
Drug: High-dose danaparoid
Normalized name: DANAPAROID
DrugBank: Danaparoid (DB06754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose danaparoid
Study: 7539233
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (low-dose danaparoid, high-dose danaparoid, unfractionated heparin)
Study: 31599059
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% ketoconazole cream
Study: 6752876
Drug: Pirprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirprofen (800 mg/day)
Study: 373942
Drug: Aspirin (3,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3,600 mg/day)
Study: 31627938
Drug: Approximately 1
Normalized name: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.-METHOXYPOLY(O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 1 gram/day of purified fish oil containing 840 mg/day of EPA and docosahexaenoic acid (DHA)
Study: 30766593
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion at 0.4mcg/kg/hr
Study: 30766593
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.2mcg/kg/min
Study: 26867000
Drug: Subjective stimulant-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective stimulant-like effects
Study: 26867000
Drug: Subjective sedative-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective sedative-like effects
Study: 23013107
Drug: Transcranial laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial laser therapy with the NeuroThera® Laser System
Study: 23013107
Drug: Sham transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham transcranial laser therapy procedure
Study: 22777879
Drug: Various obesity
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various obesity treatments (specific treatments not detailed)
Study: 11899591
Drug: Alprazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.25 mg) administered twice daily to the treated group
Study: 7653806
Drug: Eltanolone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanolone (0.5 mg/kg) + fentanyl (3 micrograms/kg)
Study: 7653806
Drug: Thiopental (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (3 mg/kg) + fentanyl (3 micrograms/kg)
Study: 795564
Drug: Gonadotrophin releasing
Normalized name: Gonadotrophin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin releasing hormone (500 mug subcutaneously every 8 h for 4 weeks)
Study: 27883311
Drug: Higher optimism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher optimism regarding the effects of HIV treatments on HIV transmission
Study: 16425125
Drug: Single-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nevirapine plus zidovudine (SD-NVP + ZDV)
Study: 16425125
Drug: Single-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nevirapine (SD-NVP) alone
Study: 12830834
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (ME)
Study: 1650036
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) with polymyxin, amphotericin, tobramycin, and intravenous cefotaxime
Study: 10999057
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic therapy (Control)
Study: 28455894
Drug: Community Treatment
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Treatment Program (CTP)
Study: 28455894
Drug: Individual Treatment
Normalized name: Alex Rubber Tip Individual Pack 3/4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Treatment Program (ITP)
Study: 23701746
Drug: AV7909 Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909)
Study: 23701746
Drug: AV7909 Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909)
Study: 23701746
Drug: AV7909 Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909)
Study: 23701746
Drug: AV7909 Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909)
Study: 23701746
Drug: BioThrax (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioThrax (0.5 mL)
Study: 23701746
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (0.5 mL)
Study: 17364078
Drug: Therapies (Riquent,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies (Riquent, belimumab, mycophenolate mofetil, dehydroepiandrosterone, oestrogen therapy, cholesterol-lowering diet)
Study: 15206062
Drug: scIL-2 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: scIL-2 at a dose of 1.5 mIU (n=36)
Study: 15206062
Drug: scIL-2 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: scIL-2 at a dose of 4.5 mIU (n=36)
Study: 15206062
Drug: scIL-2 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: scIL-2 at a dose of 7.5 mIU (n=37)
Study: 12394945
Drug: Early high-volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high-volume hemofiltration (72-96 L per 24 hrs)
Study: 12394945
Drug: Early low-volume
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early low-volume hemofiltration (24-36 L per 24 hrs)
Study: 12394945
Drug: Late low-volume
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late low-volume hemofiltration (24-36 L per 24 hrs)
Study: 9891536
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy (52 cases)
Study: 2919938
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI) with a spacer
Study: 26581079
Drug: Comparison with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison with psychosomatic and behavioral medicine journals
Study: 11549097
Drug: Irbesartan 75
Normalized name: irbesartan 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 75 mg (oral capsule or intravenous infusion)
Study: 8142265
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (FT + TAM 20 mg day‐1 for 2 years after DOX administration)
Study: 8142265
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (FT 50 mg day‐1 for 2 years after DOX administration)
Study: 8142265
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (FT + TAM 20 mg day‐1 for 2 years)
Study: 23672269
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg once daily at bedtime (qhs)
Study: 26356615
Drug: Cytoflavin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (20 ml per day for 10 days)
Study: 26356615
Drug: Cytoflavin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (10 ml per day from 11th to 20th day)
Study: 26356615
Drug: Cytoflavin (20-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (20-day therapy)
Study: 26356615
Drug: Cytoflavin (10-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (10-day therapy)
Study: 23496988
Drug: Improved oral
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved oral health care and a diet of increased consistency
Study: 22127965
Drug: Continuous sequential
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sequential estrogen plus progestin (n = 52)
Study: 19851520
Drug: Parnaparin (3200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin (3200, 4250, 6400, or 12800 IUaXa) administered subcutaneously once daily for 3 to 5 days to 6 months
Study: 17384437
Drug: Tolvaptan 30
Normalized name: tolvaptan 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 30 mg once per day (n = 2072)
Study: 17384437
Drug: Tolvaptan 30
Normalized name: tolvaptan 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 30 mg once per day
Study: 8630518
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH 0.1 IU/kg body wt per day)
Study: 1569442
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (one cycle)
Study: 29231300
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (flying needling therapy + clomiphene)
Study: 29231300
Drug: Flying needling
Normalized name: house fly extract
DrugBank: Musca domestica (DB10688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flying needling therapy group
Study: 29231300
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (clomiphene)
Study: 29231300
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group and Flying needling therapy group
Study: 2506598
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg PO lorazepam
Study: 28570966
Drug: Family‐focused therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family‐focused therapy for adolescents (FFT‐A) plus pharmacotherapy
Study: 28570966
Drug: Brief psychoeducation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychoeducation (enhanced care, or EC) plus pharmacotherapy
Study: 25644344
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplementation (27 g/supplement, twice daily)
Study: 25644344
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplementation (26 g/supplement, twice daily)
Study: 25644344
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (25 g maltodextrin/supplement, twice daily)
Study: 10828727
Drug: Ropinirole 0.5
Normalized name: ropinirole 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole 0.5 mg
Study: 8251279
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg (Navoban)
Study: 29864432
Drug: Dexamethasone 60
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 60 mg over 3 perioperative days
Study: 25899914
Drug: Individualized loading
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized loading dose (LD) regimen of cholecalciferol, 50,000 IU twice a week, followed by a monthly maintenance dose of either 50,000 or 25,000 IU
Study: 25899914
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose (DD) regimen of cholecalciferol, 800 IU daily for 26 weeks
Study: 8575576
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide doses
Study: 1827799
Drug: Acitretin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (50 mg/day) plus UVB therapy
Study: 1827799
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus UVB therapy
Study: 31587979
Drug: Core decompression
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Core decompression and PRP‐incorporated autologous granular bone grafting (treatment group)
Study: 19164343
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg desloratadine
Study: 23053062
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg desloratadine
Study: 19564277
Drug: Amoxicillin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (90 mg/kg) with potassium clavulanate (6.4 mg/kg)
Study: 16303845
Drug: Metyrapone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (500 mg p.o. qid for 2 weeks)
Study: 15518626
Drug: HMR 3339
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMR 3339 (other doses)
Study: 2496577
Drug: Flunarizine 15
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 15 mg daily
Study: 21973
Drug: 6-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-valent pneumococcal vaccine
Study: 21973
Drug: 12-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-valent pneumococcal vaccine
Study: 7138751
Drug: Metoprolol SA
Normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol SA 200 mg
Study: 7138751
Drug: Metoprolol SR
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol SR 200 mg
Study: 7138751
Drug: Conventional Metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Metoprolol 200 mg
Study: 30424742
Drug: Complex intervention
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex intervention combining behavioural support, nicotine replacement therapy, and personalized feedback on home air quality
Study: 26228466
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (90 min once weekly for 10 weeks)
Study: 23176560
Drug: Monthly motivation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly motivation feedback generated by clinicians (additional to treatment as usual)
Study: 7789486
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of BAY u 3405 (TP receptor antagonist)
Study: 7789486
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of BAY u 3405 (TP receptor antagonist)
Study: 7789486
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of BAY u 3405 (TP receptor antagonist)
Study: 2189866
Drug: Ketotifen (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (oral administration for 3 months)
Study: 23324510
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing of insulin glargine (0.5 units/kg)
Study: 23324510
Drug: Percentage-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percentage-based dosing of insulin glargine (50% of TDI)
Study: 26233335
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (84 μg)
Study: 26233335
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (84 μg)
Study: 9460345
Drug: Antibody-targeted therapies
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-targeted therapies
Study: 3440774
Drug: Single 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 g doses of cefonicid followed by ethanol challenges
Study: 3440774
Drug: Three consecutive
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three consecutive 1 g doses of cefonicid given at 24 h intervals followed by ethanol challenge
Study: 25964168
Drug: Live virus
Normalized name: rubella and mumps live virus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live virus zoster vaccine (ZV)